Low-molecular-weight heparins and cancer: Focus on antitumoral effect
Key result
This review highlights preclinical and clinical evidence suggesting that low-molecular-weight heparins may improve survival in cancer patients through direct effects on tumor biology.
Why the study?
Do low-molecular-weight heparins improve survival in patients with malignancy through antitumoral effects?
Population
Patients with malignancy
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
LMWHs should not yet change cancer management for survival; leaves open antitumoral benefits pending randomized confirmation.
Structured PICO
Do low-molecular-weight heparins improve survival in patients with malignancy through antitumoral effects?
P
Population
Patients with malignancy
I
Intervention
Low-molecular-weight heparins (LMWHs)
O
Outcome
Survival benefits / antitumoral effect
This review highlights the potential for low-molecular-weight heparins to provide survival benefits in cancer patients via direct antitumoral mechanisms independent of their antithrombotic effects.
Cite This Study
Franchini et al. (2015) conducted a review in Cancer and venous thromboembolism. Low-molecular-weight heparins (LMWHs) was evaluated on Survival benefits and antitumoral effect. This review highlights preclinical and clinical evidence suggesting that low-molecular-weight heparins may improve survival in cancer patients through direct effects on tumor biology.